These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 16382264)

  • 1. Do all patients with coronary artery disease benefit from angiotensin converting enzyme inhibitors?
    Shah AD; Arora RR
    J Cardiovasc Pharmacol Ther; 2005 Dec; 10(4):281-3. PubMed ID: 16382264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do ACE inhibitors have a real role in coronary artery disease?
    Cardiovasc J S Afr; 2003; 14(3):156. PubMed ID: 12934579
    [No Abstract]   [Full Text] [Related]  

  • 3. Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril.
    Dinicolantonio JJ; Lavie CJ; O'Keefe JH
    Postgrad Med; 2013 Jul; 125(4):154-68. PubMed ID: 23933903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease.
    Brugts JJ; de Maat MP; Boersma E; Witteman JC; van Duijn C; Uitterlinden AG; Bertrand M; Remme W; Fox K; Ferrari R; Danser AH; Simoons ML;
    Cardiovasc Drugs Ther; 2009 Apr; 23(2):171-81. PubMed ID: 19082699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tailored therapy of ACE inhibitors in stable coronary artery disease: pharmacogenetic profiling of treatment benefit.
    Brugts JJ; Boersma E; Simoons ML
    Pharmacogenomics; 2010 Aug; 11(8):1115-26. PubMed ID: 20712529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial.
    Brugts JJ; Boersma E; Chonchol M; Deckers JW; Bertrand M; Remme WJ; Ferrari R; Fox K; Simoons ML;
    J Am Coll Cardiol; 2007 Nov; 50(22):2148-55. PubMed ID: 18036453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue angiotensin-converting enzyme inhibitors: are they more effective than serum angiotensin-converting enzyme inhibitors?
    Shah AD; Arora RR
    Clin Cardiol; 2005 Dec; 28(12):551-5. PubMed ID: 16405197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should all patients with coronary disease receive angiotensin-converting-enzyme inhibitors?
    White HD
    Lancet; 2003 Sep; 362(9386):755-7. PubMed ID: 13678865
    [No Abstract]   [Full Text] [Related]  

  • 9. Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease.
    Brugts JJ; Isaacs A; Boersma E; van Duijn CM; Uitterlinden AG; Remme W; Bertrand M; Ninomiya T; Ceconi C; Chalmers J; MacMahon S; Fox K; Ferrari R; Witteman JC; Danser AH; Simoons ML; de Maat MP
    Eur Heart J; 2010 Aug; 31(15):1854-64. PubMed ID: 20538738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A population-based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors.
    Cressman AM; Macdonald EM; Fernandes KA; Gomes T; Paterson JM; Mamdani MM; Juurlink DN;
    Br J Clin Pharmacol; 2015 Oct; 80(4):662-9. PubMed ID: 25980448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].
    Rapezzi C; Ciliberti P; Graziosi M; Riva L
    Ital Heart J; 2005 Nov; 6 Suppl 7():40S-47S. PubMed ID: 16485516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should angiotensin-converting enzyme-inhibitors be used to improve outcome in patients with coronary artery disease and 'preserved' left ventricular function?
    Fox K; Ferrari R; Yusuf S; Borer JS
    Eur Heart J; 2006 Sep; 27(18):2154-7. PubMed ID: 16905555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function.
    Bertrand ME; Remme WJ; Fox KM; Ferrari R; Simoons ML;
    Int J Cardiol; 2007 Sep; 121(1):57-61. PubMed ID: 17270296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model.
    Oemrawsingh RM; Akkerhuis KM; Van Vark LC; Redekop WK; Rudez G; Remme WJ; Bertrand ME; Fox KM; Ferrari R; Danser AH; de Maat M; Simoons ML; Brugts JJ; Boersma E;
    J Am Heart Assoc; 2016 Mar; 5(3):e002688. PubMed ID: 27021566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
    Teo K; Yusuf S; Sleight P; Anderson C; Mookadam F; Ramos B; Hilbrich L; Pogue J; Schumacher H;
    Am Heart J; 2004 Jul; 148(1):52-61. PubMed ID: 15215792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combine EUROPA and HOPE.
    Fuller JA
    Lancet; 2003 Dec; 362(9399):1937. PubMed ID: 14667761
    [No Abstract]   [Full Text] [Related]  

  • 17. [Ischemic heart disease with low risk of vascular complications -- a novel indication for angiotensin converting enzyme inhibitors (results of EUROPA trial)].
    Perepech NB
    Kardiologiia; 2004; 44(3):106-10. PubMed ID: 15489840
    [No Abstract]   [Full Text] [Related]  

  • 18. [Scientific value of the EUROPA Study: mechanisms of beneficial effect of perindopril in atherosclerosis].
    Karpov IuA
    Kardiologiia; 2005; 45(2):86-9. PubMed ID: 15798719
    [No Abstract]   [Full Text] [Related]  

  • 19. Lymphocyte-suppressing action of angiotensin-converting enzyme inhibitors in coronary artery disease patients with normal blood pressure.
    Krysiak R; Okopień B
    Pharmacol Rep; 2011; 63(5):1151-61. PubMed ID: 22180357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The EUROPA trial.
    Boos C
    Lancet; 2003 Dec; 362(9399):1935; author reply 1936-7. PubMed ID: 14667756
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.